Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.005
Sell
RSI(14)
50.666
Neutral
STOCH(KDJ)(9,3,3)
51.628
Buy
ATR(14)
0.105
High Vlolatility
CCI(14)
-0.267
Neutral
Williams %R
44.186
Buy
TRIX(12,20)
-0.192
Sell
StochRSI(14)
100.000
Overbought
Cronos Group Inc
CRON2.640USD
+0.080+3.13%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
1.01BMarket Cap
27.91P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Cronos Group Inc
Currency: USD Updated: 2026-02-06Key Insights
Cronos Group Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 79 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 2.90.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Cronos Group Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Cronos Group Inc Highlights
StrengthsRisks
Cronos Group Inc. is a global cannabinoid company engaged in building disruptive intellectual property by advancing cannabis research, technology and product development. The Company’s diverse international brand portfolio includes Spinach, PEACE NATURALS and Lord Jones. Spinach is a mainstream adult-use cannabis brand with a portfolio that includes cannabinoid products in a wide range of formats, including dried flower, pre-rolls, vaporizers, edibles and tinctures. Lord Jones is a premium adult-use cannabis brand. The Lord Jones brand portfolio includes cannabis products in the pre-roll, vaporizer and edible categories. Lord Jones Ice Water Hash Fusions pre-rolls feature flower and terpene-rich ice water hash and are fitted with a branded ceramic tip. PEACE NATURALS is a global medical brand engaged in producing cannabis products. The Company distributes products under the PEACE NATURALS brand for the Canadian market and the Israeli, German, and United Kingdom medical markets.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 35.58% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 27.91, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 61.74M shares, increasing 0.25% quarter-over-quarter.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.16.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
2.900
Target Price
+13.28%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of Cronos Group Inc is 8.68, ranking 47 out of 159 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 36.34M, representing a year-over-year increase of 6.06%, while its net profit experienced a year-over-year increase of 210.91%.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.32
Operational Efficiency
10.00
Growth Potential
8.62
Shareholder Returns
7.44
Cronos Group Inc's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of Cronos Group Inc is 6.60, ranking 120 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 27.91, which is 117.64% below the recent high of 60.75 and 172.29% above the recent low of -20.18.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 79/159
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of Cronos Group Inc is 7.00, ranking 118 out of 159 in the Pharmaceuticals industry. The average price target is 2.90, with a high of 2.90 and a low of 2.90.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
2.900
Target Price
+13.28%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
173
Total
6
Median
8
Average
Company name
Ratings
Analysts
Cronos Group Inc
CRON
2
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Vertex Pharmaceuticals Inc
VRTX
33
Eli Lilly and Co
LLY
33
Gilead Sciences Inc
GILD
31
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of Cronos Group Inc is 7.42, ranking 56 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 2.85 and the support level at 2.42, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
2.572
Buy
MA10
2.602
Buy
MA20
2.622
Buy
MA50
2.676
Sell
MA100
2.608
Buy
MA200
2.367
Buy
Institutional Confidence
Currency: USD Updated: 2026-02-06Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Cronos Group Inc is 5.11, ranking 76 out of 159 in the Pharmaceuticals industry. The company's beta value is 1.19. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.19
VaR
+4.92%
240-Day Maximum Drawdown
+23.24%
240-Day Volatility
+52.04%
Return
Best Daily Return
60 days
+14.74%
120 days
+14.74%
5 years
+25.66%
Worst Daily Return
60 days
-6.73%
120 days
-7.38%
5 years
-15.48%
Sharpe Ratio
60 days
+0.53
120 days
+0.15
5 years
-0.18
Risk Assessment
Maximum Drawdown
240 days
+23.24%
3 years
+46.36%
5 years
+82.12%
Return-to-Drawdown Ratio
240 days
+1.61
3 years
+0.26
5 years
-0.17
Skewness
240 days
+1.56
3 years
+1.04
5 years
+0.77
Volatility
Realised Volatility
240 days
+52.04%
5 years
+55.86%
Standardised True Range
240 days
+3.70%
5 years
+5.79%
Downside Risk-Adjusted Return
120 days
+26.90%
240 days
+26.90%
Maximum Daily Upside Volatility
60 days
+51.31%
Maximum Daily Downside Volatility
60 days
+26.22%
Liquidity
Average Turnover Rate
60 days
+0.60%
120 days
+0.52%
5 years
--
Turnover Deviation
20 days
+115.57%
60 days
+23.73%
120 days
+7.72%
Peer Comparison
Pharmaceuticals
Cronos Group Inc
CRON
6.86 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mckesson Corp
MCK
9.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.92 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
8.86 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.70 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
